NASDAQ:MYNZ Mainz Biomed (MYNZ) Stock Price, News & Analysis $0.24 -0.01 (-3.97%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends About Mainz Biomed Stock (NASDAQ:MYNZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Mainz Biomed alerts:Sign Up Key Stats Today's Range$0.23▼$0.2650-Day Range$0.20▼$0.4752-Week Range$0.19▼$3.39Volume2.59 million shsAverage Volume729,990 shsMarket Capitalization$2.91 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingModerate Buy Company OverviewMainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Read More… Next opportunity for crypto millions (Ad)October isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…Go here to discover the coin that could define this historic bull run with gains kicking off this mo Mainz Biomed Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks46th Percentile Overall ScoreMYNZ MarketRank™: Mainz Biomed scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingMainz Biomed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMainz Biomed has received no research coverage in the past 90 days.Read more about Mainz Biomed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Mainz Biomed is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mainz Biomed is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMainz Biomed has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Mainz Biomed's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.20% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently increased by 75.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMainz Biomed does not currently pay a dividend.Dividend GrowthMainz Biomed does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.20% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently increased by 75.93%, indicating that investor sentiment is decreasing significantly. News and Social Media2.3 / 5News Sentiment0.12 News SentimentMainz Biomed has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Mainz Biomed this week, compared to 2 articles on an average week.Search Interest3 people have searched for MYNZ on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mainz Biomed insiders have not sold or bought any company stock.Percentage Held by Insiders18.20% of the stock of Mainz Biomed is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Mainz Biomed's insider trading history. Receive MYNZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter. Email Address MYNZ Stock News HeadlinesMainz Biomed $MYNZ Introduces The Newest Addition To Their TeamOctober 4 at 4:55 PM | msn.comMainz Biomed (NASDAQ:MYNZ) Stock, Short Interest ReportOctober 2, 2024 | benzinga.comNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… October 6, 2024 | Crypto 101 Media (Ad)The Covid Era Tech Promises To Reinvent Cancer TreatmentOctober 1, 2024 | finance.yahoo.comMainz Biomed plant FDA-Studie für Krebstest im Jahr 2025October 1, 2024 | de.investing.comEQS-News: Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025October 1, 2024 | markets.businessinsider.comMainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025October 1, 2024 | globenewswire.comMainz Biomed (NASDAQ:MYNZ) Trading 5.3% Higher September 28, 2024 | americanbankingnews.comSee More Headlines MYNZ Stock Analysis - Frequently Asked Questions How have MYNZ shares performed this year? Mainz Biomed's stock was trading at $1.16 at the beginning of 2024. Since then, MYNZ stock has decreased by 79.1% and is now trading at $0.2419. View the best growth stocks for 2024 here. How were Mainz Biomed's earnings last quarter? Mainz Biomed (NASDAQ:MYNZ) posted its quarterly earnings data on Tuesday, August, 15th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.14. The company earned $0.25 million during the quarter, compared to the consensus estimate of $0.25 million. Mainz Biomed had a negative trailing twelve-month return on equity of 488.05% and a negative net margin of 2,934.82%. When did Mainz Biomed IPO? Mainz Biomed (MYNZ) raised $10 million in an initial public offering on Friday, November 5th 2021. The company issued 2,000,000 shares at $4.00-$6.00 per share. Boustead Securities acted as the underwriter for the IPO. How do I buy shares of Mainz Biomed? Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/15/2023Today10/06/2024Next Earnings (Estimated)11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MYNZ CUSIPN/A CIK1874252 Webmainzbiomed.com Phone49-6131-554-2860FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,140.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,300,000.00 Net Margins-2,934.82% Pretax Margin-2,938.10% Return on Equity-488.05% Return on Assets-145.77% Debt Debt-to-Equity Ratio0.36 Current Ratio0.97 Quick Ratio0.91 Sales & Book Value Annual Sales$895,479.00 Price / Sales3.24 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book0.90Miscellaneous Outstanding Shares12,010,000Free FloatN/AMarket Cap$2.91 million OptionableNot Optionable Beta0.09 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:MYNZ) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.